共 32 条
- [1] Karvouni E(2003)Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions J Am Coll Cardiol 41 26-32
- [2] Katritsis DG(2002)Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials Lancet 359 189-198
- [3] Ioannidis J(2004)Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors Curr Hematol Rep. 3 143-147
- [4] Boersma E(2000)Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis Am Heart J 140 206-211
- [5] Harrington RA(2004)Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting Circulation 109 2203-2206
- [6] Moliterno DJ(2000)Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and re-treatment Am Heart J 139 S38-S45
- [7] Abrams CS(1981)A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther 30 239-245
- [8] Cines DB(2002)Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa Blood 100 2071-2076
- [9] Dasgupta H(2002)Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximabcoated platelets Blood 99 2054-2059
- [10] Blankenship JC(2001)Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization New Engl J Med 344 1888-1894